Background: FETAL Growth Restriction (FGR) is a problem where the fetus fails to attain its normal growth potential and this affects nearly about 8% of all pregnancies Solcoseryl is a protein-free and antigen-free haemodialysate derived from calf blood. It is thought to activate the cellular respiratory chain leading to better oxygen utilisation by the tissues. Aim of the study was to compare between Solcoseryl and low molecular weight heparin in treatment of patients suffered from intrauterine growth restriction due to placental insufficiency.
Methods: The patients who included in this study were divided randomly via (computer-generated random numeric tables prepared by a statistician) into two groups with 35 cases in each group. Group (A) (Solcoseryl. Group): 35 women received Solcoseryl ampule 42.5 mg intravenous infusion (Misr Compony) Once daily for 3 weeks. Group (B) (LMWH (Clexan) Group): 35 women received single dose of LMWH subcutaneous (clexane 40 mg) once daily for 3 weeks.
Results: There is a significant decrease regarding umbilical artery RI in both groups but the significant decrease was better in group A compared to group B. Otherwise, there is no significant difference between the two groups umbilical artery RI at different time intervals. there is significant increase in Gestational age and birth weight in patients who receive solcoseryl and LMWH .There is an improvement in Doppler indices of both (UA and MCA) in both group but is better in solcoseryl than LMWH and significant increase in Apgar score at 1min and 5 min in both groups but is better in solcoseryl than LMWH.
Conclusions: In this study, LMWH and Solcoseryl administration in IUGR fetuses enhance Doppler indices, promote significant increase in Gestational age so enhance neonatal birth weight.
VP35.20: What is the best way to distinguish the two phenotypes of fetal growth restriction? Umbilical artery Doppler versus gestational age
